(CercleFinance.com) – Valneva announces that it suffered a net loss of 143.3 million euros in 2022, compared to a loss of 73.4 million the previous year, as well as a negative adjusted EBITDA which fell from 47, 1 to 69.2 million year over year.
The vaccine company specifies that at the level of its operational loss of 113.4 million, the Covid-19 program contributed to the loss to the tune of 42.8 million in 2022 after having generated a profit of 3.9 million in 2021. .
Total revenue increased 3.8% to €361.3 million, driven by an 82.3% jump in product sales thanks to the continued recovery in the traveler market, as well as sales vaccine against Covid-19 in Europe and Bahrain.
For 2023, Valneva indicates that it anticipates total sales of between 220 and 260 million euros, of which 130 to 150 million in product sales, including marginal sales of vaccines against Covid-19, and R&D expenses between 70 and 90 million.